Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Atrial Fibrillation Market $29.1 Billion by 2027

The global market for atrial fibrillation predicted to attain $29.1 billion by 2027 growing at the rate of 11.4% CAGR, driven by increasing incidence and prevalence of disorders causing atrial fibrillation such as hypertension and obesity, rising geriatric population and age-related disorders.

Global Atrial Fibrillation Market

According to American Heart Association (AHA), atrial fibrillation (A-Fib or AF) involves quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.

  • These irregular impulses cause the atria to quiver or twitch, which is known as fibrillation. This causes as an irregular, and sometimes fast, heartbeat or pulse.
    • Atrial fibrillation is a major risk factor for ischemic stroke and provokes important economic burden along with significant morbidity and mortality.
  • The global aging of the population will determine an endemic that will result in significant burden on health care systems and physicians taking care of these populations
    • As the population ages globally, atrial fibrillation (AF) is predicted to affect 6–12 million people in the USA by 2050 and 17.9 million in Europe by 2060.
      • The reasons for the increase in the prevalence of AF remain elusive and are related to multiple factors including; enhanced detection, increased incidence, and greater survival after onset of AF.
Atrial-Fibrillation-Prevalence

Treatments for atrial fibrillation include medicines to control heart rate and reduce the risk of stroke, and procedures such as cardioversion to restore normal heart rhythm or alter the heart’s electrical system.

  • Anti-arrhythmics medicines can control atrial fibrillation by restoring a normal heart rhythm and controlling the rate at which the heart beats.
    • In general, the prescription medications include beta-blockers to decrease heart rate, calcium channel blockers to relax arterial muscles and decrease overall heart rate, sodium or potassium channel blockers to control heart rhythm, digitalis glycosides to strengthen heart contractions, and blood thinners to prevent blood clots from forming.
      • The non-vitamin K oral anticoagulants (NOACs) are the preferred blood thinners for AFib, such as rivaroxaban (Xarelto) and apixaban (Eliquis).
Atrial Fibrillation Market

The global atrial fibrillation market report provides market size estimates ($million 2017 to 2027), market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for atrial fibrillation segmented by treatment type [pharmacological treatment (anti-arrhythmic drugs, anti-coagulant drugs)], non-pharmacological treatment [catheter ablation procedures (cryoablation, high intensity focused ultrasound, laser ablation, microwave ablation, radiofrequency ablation), maze surgery, and electric cardioversion], and geography.

  • Based on the broader treatment types, the pharmacological drug treatments segment accounted for the largest share of the total market, as these treatments are more frequently administered to the patients suffering from atrial fibrillation and are a cheaper alternative to non-pharmacological procedures.
    • Anti-coagulant drugs sub-segment dominated the pharmacological treatments segment and the introduction of new drugs for atrial fibrillation further expected to increase its market share in the coming years.
  • Among the non-pharmacological treatment segment, the catheter ablation sub-segment led the global market and it is expected to witness fastest growth rate during the forecast period, being more expensive, minimally invasive (non-surgical) nature of procedures, as well as faster patient recovery time and lower risks compared to surgical and/or electric cardioversion procedures.
    • The radiofrequency based catheter ablation treatment sub-segment for atrial fibrillation accounted for the largest revenue share of the total market, being relatively less time consuming, higher success rate and cheaper alternative to other advanced procedures.

The global atrial fibrillation market research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • Geographically, the North America and Europe regions dominated the global AF market, owing higher prevalence of atrial fibrillation, high cost of ablation devices, rapid adoption of ablation technologies, and increasing healthcare expenditure coupled with favorable reimbursement scenario in the developed countries.
    • However, the Asia Pacific region predicted to register the fastest CAGR in the next few years, attributed to increasing prevalence of atrial fibrillation, rising disposable income, improving healthcare infrastructure and access to better medical care in the developing countries.

The global atrial fibrillation report also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and/or services offered, and recent trends in strategic management. 

Major competitors operating in the global atrial fibrillation market and profiled in the report are Abbott Laboratories, Inc. (St. Jude Medical, Inc./Endosense/Irvine Biomedical, Inc./Topera, Inc.), AtriCure, Inc., (Endoscopic Technologies, Inc./Estech/SentreHEART, Inc.), Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, CardioFocus, Inc., Johnson and Johnson (Biosense Webster, Inc.), Medtromic plc, Sanofi S.A.

  • Treatment Type
    • Pharmacological Treatment
      • Anti-Arrhythmic Drugs
      • Anti-Coagulant Drugs
    • Non-Pharmacological Treatment
      • Catheter Ablation Procedures
        • Cryoablation
        • High Intensity Focused Ultrasound (HIFU)
        • Laser Ablation
        • Microwave Ablation
        • Radiofrequency Ablation
      • Maze Surgery
      • Electric Cardioversion
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World 
  • Company Profiles
    • Abbott Laboratories, Inc. (St. Jude Medical, Inc./Endosense//Irvine Biomedical, Inc./Topera, Inc.)
    • AtriCure, Inc. (Endoscopic Technologies, Inc./Estech/SentreHEART, Inc.)
    • Boehringer Ingelheim GmbH
    • Boston Scientific Corporation
    • Bristol-Myers Squibb Company
    • CardioFocus, Inc.
    • Johnson and Johnson (Biosense Webster, Inc.)
    • Medtronic plc
    • Sanofi S.A.

To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/atrial-fibrillation-market/

Related publications:



    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]